ADOA represents an estimated >$2 billion p.a. addressable market(7) with notreatment options available for patients today
(7) Estimated market in Australian dollars based on a target patient population of 10,000 in the Western World and median orphan drug pricing of US$150,000 per patient per annum (EvaluatePharma. Orphan Drug Report. 2019.)
Co has stated that the transaction window is now open for a deal with more deals being done in phase 1 & 2.
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.025(2.08%) |
Mkt cap ! $714.4M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.23 | $1.20 | $411.5K | 342.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 872 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.23 | 20912 | 3 |
View Market Depth
| Last trade - 11.00am 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |